NYSE: MRK - Invest Million

Merck’s (NYSE: MRK) Molnupiravir Shows Reduction In Virus Infection

Merck & Co., Inc. (NYSE: MRK) has reported positive results from its Phase 2a to assess the safety of Molnupiravir. MRK is developing Molnupiravir jointly with Ridgeback Bio.

Merck & Co Inc

Merck (NYSE: MRK) Announces Acquisition Of Pandion

Merck & Co., Inc. (NYSE: MRK) revealed that it has signed an agreement with Pandion to acquire the clinical-stage biotechnology firm. Merck will buy Pandion through its subsidiary for $60 per share in cash.

Nektar Therapeutics

Nektar (NASDAQ: NKTR) Inks Collaboration And Supply Agreement With Merck

Nektar Therapeutics (NASDAQ: NKTR) disclosed that it has signed a clinical study partnership and supply agreement with Merck & Co. (NYSE: MRK).

Breaking News

Merck & Co (NYSE: MRK) Announces Accquisition Of OncoImmune

Merck & Co, Inc. (NYSE: MRK) is planning to buy all the outstanding shares of OncoImmune for an upfront payment of $425 million in cash. Additionally, the shareholders of OncoImmune will be able to get the sales-based payment upon successfully achieving set targets. OncoImmune

Breaking News

Merck & Co’s (NYSE: MRK) Keytruda Receives FDA Green Signal To Treat Breast Cancer

Merck & Co’s., Inc. (NYSE: MRK) has declared that its Keytruda has received the approval of the FDA. FDA has given the green signal for the treatment of triple-negative breast cancer (TNBC) with Keytruda in combination with chemotherapy. FDA has supported Keytruda after